



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Fabio Cicero
ALWP Chair
Italy

Major achievements

The ALWP continues its activities through the active engagement of its members and the support of the EBMT staff. The collaborative efforts within the Working Party have enabled the successful development and completion of several important studies during the past year, addressing clinically relevant questions in the field of HCT for patients with acute leukaemia.

A number of studies have focused on donor selection strategies, including comparative studies evaluating outcomes following transplantation from younger haploidentical donors versus older matched unrelated donors, as well as donor selection in elderly patients. Additional studies have evaluated the prognostic impact of cytogenetic and molecular risk stratification, including outcomes according to the ELN 2022 adverse cytogenetic subgroups and the clinical relevance of specific genetic categories.

Further studies have explored strategies aimed at optimizing transplant approaches through risk-adapted methodologies. These include studies assessing cytogenetic- and molecular risk-driven conditioning intensity and analyses evaluating the impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide-based GVHD prophylaxis. In addition, analyses on evolving treatment practices, including the increasing use of pharmacologic maintenance therapy following allo-HCT in patients with AML.

Collectively, these and many other studies contribute to an expanding portfolio of ALWP research. The contributions of ALWP members, study investigators, and the EBMT staff are gratefully acknowledged. The ALWP remains committed to fostering collaborative research within the EBMT network with the aim of further advancing the field of transplantation in acute leukaemia.

Principal research studies

[Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Ali Bazarbachi](#)

[Impact of pre-transplant induction cycles on post-transplant outcomes in patients with ALL: a study from the ALWP EBMT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Lymphatic Leukaemia \(ALL\)](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Dr. Juan Montoro](#)

[Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Dr. Arnon Nagler](#)

Key publications

[2025](#)

[Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow](#)

[Transplantation](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Jaime Sanz](#)

[Journal](#)

Haematologica.

2025

Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Group

Acute Leukemia Working Party (ALWP)

1st listed author

Yishan Ye

Journal

Am J Hematol.

2025

TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Group

Acute Leukemia Working Party (ALWP)

Global Committee

1st listed author

Lin Li

Journal

Haematologica.

2025

Improved post-transplant outcomes since 2000 for Ph-positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party

Group

Acute Leukemia Working Party (ALWP)

1st listed author

Ali Bazarbachi

Journal

Hemasphere.

2025

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic

[Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Jordi Esteve](#)

[Journal](#)

[Am J Hematol.](#)

[See the full list of the ALWP 2025 publications](#)



Indicators

	2023	2024	2025
Impact factor	277.60	228.00	210.60
Oral presentations	23	27	15
Poster presentations	22	25	31
Educational events	2	1	3

Major educational events



[Event](#)

51st Annual Meeting of the EBMT



[Event](#)

**Acute Leukaemia and Cellular Therapy and Immunobiology
Working Parties Joint Transplant Programme Track at the 8th
Annual Meeting of the IACH**

Oct 09, 2025 - Oct 11, 2025 / Paris, France

[Discover more](#)

Harmonisation Workshop ALWP - 29-30 September 2025

[VISIT THE ALWP WEBPAGE](#)